<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/29E60961-02D0-4C26-8D0B-D1C83013860B"><gtr:id>29E60961-02D0-4C26-8D0B-D1C83013860B</gtr:id><gtr:name>Crystec Limited</gtr:name><gtr:address><gtr:line1>NORCROFT BUILDING, , RICHMOND ROAD</gtr:line1><gtr:city>BRADFORD</gtr:city><gtr:postCode>BD7 1DP</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/29E60961-02D0-4C26-8D0B-D1C83013860B" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>29E60961-02D0-4C26-8D0B-D1C83013860B</gtr:id><gtr:name>Crystec Limited</gtr:name><gtr:address><gtr:line1>NORCROFT BUILDING, , RICHMOND ROAD</gtr:line1><gtr:city>BRADFORD</gtr:city><gtr:postCode>BD7 1DP</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>24858.0</gtr:offerGrant><gtr:projectCost>41430.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/4164F421-2DDC-40BE-8BC0-3283D6C528BB"><gtr:id>4164F421-2DDC-40BE-8BC0-3283D6C528BB</gtr:id><gtr:firstName>Catherine</gtr:firstName><gtr:surname>Hunter</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=700664"><gtr:id>8D28ACEA-FB34-4965-9C37-CEB7EA8515DE</gtr:id><gtr:title>Novel treatment for Raynaud's phenomena</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Market</gtr:grantCategory><gtr:grantReference>700664</gtr:grantReference><gtr:abstractText>Crystec propose a re-purposed therapy for the treatment of Raynaud's Phenomenon.</gtr:abstractText><gtr:fund><gtr:end>2016-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2016-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>24858</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">700664</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>